• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Cosmos Health Inc.

    8/15/25 6:03:44 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care
    Get the next $COSM alert in real time by email
    NT 10-Q 1 cosm_nt10q.htm NT 10-Q cosm_nt10q.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C.

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

    SEC File Number: 000-54436

    CUSIP Number: 221413206

     

    (Check one:)

    ☐ Form 10-K

    ☐ Form 20-F

    ☐ Form 11-K

    ☒ Form 10-Q

    ☐ Form 10-D

    ☐ Form N-SAR

    ☐ Form N-CSR

     

     

    For Period Ended: June 30, 2025

     

     

     

     

    ☐

    Transition Report on Form 10-K

     

    ☐

    Transition Report on Form 20-F

     

    ☐

    Transition Report on Form 11-K

     

    ☐

    Transition Report on Form 10-Q

     

    ☐

    Transition Report on Form N-SAR

     

     

     

     

    For the Transition Period Ended: _________________

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  Not applicable

     

     

    PART I - REGISTRANT INFORMATION

     

    Full Name of Registrant: Cosmos Health Inc.

    Former Name if applicable: Cosmos Holdings, Inc.

    Address of Principal Executive Office: 5 Agiou Georgiou Str, Pilea, Thessaloniki, Greece

     

     

     

     

    PART II - RULE 12B-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed: (Check box if appropriate)

     

    ☒

    (a)

    The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

    ☒

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

    (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, NCSR, or the transition report or portion thereof, could not be filed within the prescribed period.

     

    Cosmos Health Inc. (the “Company”) could not complete the filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2025 due to delays in obtaining and compiling information to be included in its Form 10-Q, including, but not limited to, our XBRL filing, which delay could not be eliminated by the Company without unreasonable effort and expense.

     

    PART IV - OTHER INFORMATION

     

    (1)

    Name and telephone number of person to contact in regard to this notification:

     

    Georgios Terzis (312) 536-5469

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding twelve months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s)

     

    ☒  Yes          ☐  No

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ☐  Yes          ☒  No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     
    2

     

     

    Cosmos Health Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    COSMOS HEALTH INC.

     

     

     

     

     

    Date:  August 15, 2025

    By:

    /s/ Georgios Terzis

     

     

    Georgios Terzis

     

     

    Chief Financial Officer

     

     

     
    3

     

    Get the next $COSM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COSM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025

    CHICAGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today its financial results for the second quarter and six-month period ended June 30, 2025. Financial Highlights for the Three and Six Months Ended June 30, 2025 Income StatementCosmos Health continued its positive trajectory in Q2 2025, delivering double-digit revenue growth of 11.66% and a 51.60% increase in gross profit. The Company remains on track to meet its profitability targets, driven by strong performance across multiple business units. For the first half of 2025, gross profit rose 53.00% to

    8/18/25 12:45:23 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy

    CHICAGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today that it has commenced purchases of Ethereum (ETH), advancing its digital asset treasury reserve strategy. Pursuant to its financing facility of up to $300 million (the "Facility") with a U.S.-based institutional investor, Cosmos Health has completed its initial $1 million purchase of ETH. Greg Siokas, CEO of Cosmos Health, stated: "We are excited to begin building our ETH treasury with this inaugural purchase. By leveraging the full potential of our facility, we aim to transform Cosmos into a sign

    8/12/25 9:50:06 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy

    CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today that it has entered into a securities purchase agreement with a U.S.-based institutional investor for the issuance of up to $300 million in senior secured convertible promissory notes (the "Facility"), subject to the satisfaction or waiver of certain conditions, to support the launch of its Ethereum (ETH) digital asset treasury reserve strategy. Key Highlights: Strategic accumulation of ETH to enhance long-term shareholder value through increasing ETH-per-shareETH assets will be custodied and staked t

    8/6/25 9:20:55 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/27/25 9:33:43 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/23/25 12:18:06 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/22/25 10:33:17 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    SEC Filings

    View All

    SEC Form NT 10-Q filed by Cosmos Health Inc.

    NT 10-Q - Cosmos Health Inc. (0001474167) (Filer)

    8/15/25 6:03:44 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form PRE 14A filed by Cosmos Health Inc.

    PRE 14A - Cosmos Health Inc. (0001474167) (Filer)

    8/11/25 7:12:10 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Cosmos Health Inc. (0001474167) (Filer)

    8/11/25 6:03:23 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/27/25 9:33:43 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/23/25 12:18:06 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/22/25 10:33:17 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Cosmos Health Inc.

    SC 13G - Cosmos Health Inc. (0001474167) (Subject)

    2/14/24 3:33:29 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

    SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

    7/25/23 4:06:11 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

    CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

    4/16/25 12:45:15 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

    CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

    12/26/24 1:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

    THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded

    11/21/23 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Financials

    Live finance-specific insights

    View All

    Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

    CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

    4/30/25 12:50:09 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

    CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

    1/21/25 3:00:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Issues Letter to Shareholders

    CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

    11/12/24 12:01:41 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care